{"chunk_id": "_Drugs-in-Pregnancy-and-Lactation--Improved-Benefit-Risk-Information_-January-22--2015-Issue__chunk_17", "source": "_Drugs-in-Pregnancy-and-Lactation--Improved-Benefit-Risk-Information_-January-22--2015-Issue", "text": "so man y \nproducts on the market already have labeling similar to requirements established under the rule.   Manufacturers whose products \nare subject to the rule are responsible for updating labeling when information becomes available regarding the use of their \nproduct by pregnant or lactating women. \nGuidance: Concurrent with publishing the PLLR, FDA has issued  a Draft Guidance for Industry Pregnancy, Lactation, and \nReproductive Potential: Labeling for Human Prescription Drug and Biologica"}